Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
77
self-reported 51–200 band
Founded
2019
7 years
Legal entities
1
ABR
Office countries
2
5 addresses
Funding rounds
4
Grant · May 2025 · US$ 11.3M
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
ADVANCELL PTY LIMITED
ABN42633959010
Legal entities
Show as table · AdvanCell: 1 registry entity
| ADVANCELL PTY LIMITED | ABN 42633959010 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
Specialties
All 6 specialties
- Radiopharmaceuticals
- Radioligand Discovery
- 212Pb
- Biotechnology
- Biopharmaceuticals
- Changing the Course of Cancer
Locations
2
Countries with an office address5 addresses on record
AustraliaUnited States
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|
All codes: AU US
Addresses
- AU9/19 MacGregor Pl; Richlands, Queensland
- USSAN FRANCSICO, CA 94123
- AULevel 7, 167 Macquarie Street; Sydney, New South Wales 2000Primary
- AUUniversity of Newcastle; Newcastle, NSW
- AUQueensland Centre for Advanced Technologies; Pullenvale
Grid intelligence Members
Funding
Rounds4
Round typeGrant · non-equity funding
Amount (USD)11,300,000
Stage rank1
Investors named1
Since last round8 mo
Funding
Show as table · 4 funding rounds
| Rounds | 4 |
|---|---|
| Axis | 2019 to 2026 |
| Grant · 13 May 2025 | US$ 11.3M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under AdvanCell?
One New South Wales entity on the ABR. ADVANCELL PTY LIMITED (ABN 42 633 959 010), high confidence.
How many people work at AdvanCell?
The record holds 77 counted staff profiles at January 2026, inside the self-reported 51–200 band.
Where does AdvanCell have offices?
Five addresses on record across 2 countries. Primary: Level 7, 167 Macquarie Street, Sydney, New South Wales 2000.
Has AdvanCell raised funding?
Four rounds. Latest 13 May 2025: grant, US$11,300,000, investor Medical Research Future Fund (MRFF).
What does AdvanCell list as its specialties?
Six tags on the brand's own list, among them biotechnology.
Which companies are listed alongside AdvanCell?
36 profiles list AdvanCell as a peer — 98th percentile in Biotechnology Research. It lists ten peers of its own.